Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

Quantum BioPharma (NASDAQ: QNTM) announced that its MS drug candidate Lucid-MS, described as patented and first-in-class, is preparing to enter phase 2 clinical trials.

Rhea-AI Summary

Quantum BioPharma (NASDAQ: QNTM) announced that its MS drug candidate Lucid-MS, described as patented and first-in-class, is preparing to enter phase 2 clinical trials. The therapy takes a different approach by directly targeting the myelin sheath damaged in multiple sclerosis, a disease affecting over 2.9 million people worldwide.

Positive

• Lucid-MS positioned as patented, first-in-class MS drug candidate
• Drug aims to directly target the myelin sheath damaged in MS
• Lucid-MS preparing to enter phase 2 clinical trials
• Addresses MS, affecting more than 2.9 million people globally

Negative

• Lucid-MS is still pre–phase 2, with significant development and approval risk ahead

Argus Jun 23 session

+5.19% close to close Open Argus

Details

News Market Reaction – QNTM

On Jun 23, the day this news came out, QNTM closed 5.19% above the previous close.

Data tracked by StockTitan Argus for the Jun 23 session.

Key Figures

Brand count: 75+ brands MS prevalence: 2.9 million people Planned trial phase: Phase 2 clinical trials

Brand count

75+ brands

Size of Dynamic Brand Portfolio@IBN mentioned in editorial placement

MS prevalence

2.9 million people

Estimated global number of people living with multiple sclerosis

Planned trial phase

Phase 2 clinical trials

Lucid-MS preparing to enter Phase 2 for multiple sclerosis

Historical Context

5 past events · Latest: Jun 02

5 events

1. Jun 02

   IR/marketing agreement

   24h Move

   -2.7%

   Six‑month investor relations and marketing agreement with Stocks.news for US$250,000.

2. May 18

   Clinical study update

   24h Move

   -7.9%

   Midpoint milestone and encouraging imaging data in MS study with Mass General Hospital.

3. May 07

   Quarterly results

   24h Move

   -5.1%

   Update highlighting strengthened liquidity, reduced cash burn and cost discipline in Q1 2026.

4. Apr 22

   Commercialization update

   24h Move

   -2.9%

   Unbuzzd licensee appoints new CEO to lead nationwide rollout of hangover remedy product.

5. Apr 02

   Legal development

   24h Move

   -9.8%

   Court largely denies defendants’ motion to dismiss Quantum’s USD $700,000,000 lawsuit.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

multiple sclerosis, myelin sheath, phase 2 clinical trials

3 terms

multiple sclerosis medical

"Multiple sclerosis (“MS”) robs people of control over their own bodies"

A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

myelin sheath medical

"by directly targeting the myelin sheath that MS destroys"

A myelin sheath is the insulating layer that wraps around nerve fibers, like plastic coating around electrical wiring, allowing the brain and body to send signals quickly and efficiently. It matters to investors because damage or loss of this insulation underlies serious neurological conditions and drives demand for diagnostics, drugs and devices aimed at protecting or repairing myelin, which can influence clinical trial outcomes, regulatory approval prospects and commercial value.

phase 2 clinical trials medical

"and this new drug candidate is preparing to enter phase 2 clinical trials"

Phase 2 clinical trials are mid-stage tests of a new treatment in a larger group of patients to assess whether it works and to further evaluate safety and dosing. Think of it like a more serious test drive after basic checks: success suggests the treatment has real potential and justifies larger, more expensive late-stage trials, which can increase a drug developer’s value to investors, while failure often leads to sharp declines in outlook.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,”  please visit: https://ibn.fm/8orPm

Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability.

Now, Quantum BioPharma Ltd. is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For further information, please visit the company’s website at www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What MS treatment is Quantum BioPharma (NASDAQ: QNTM) developing as of June 23, 2026?

Quantum BioPharma is developing Lucid-MS, a patented, first-in-class multiple sclerosis drug candidate. According to Quantum BioPharma, Lucid-MS takes a different approach by directly targeting the myelin sheath that MS destroys and is preparing to enter phase 2 clinical trials.

How does Quantum BioPharma's Lucid-MS differ from current MS therapies for QNTM investors?

Lucid-MS is described as a first-in-class therapy that directly targets the myelin sheath damaged by MS. According to Quantum BioPharma, current approved treatments can slow disease progression but do not halt it, highlighting Lucid-MS’s distinct development approach.

What clinical trial stage is Lucid-MS at for Quantum BioPharma (QNTM)?

Lucid-MS is preparing to enter phase 2 clinical trials. According to Quantum BioPharma, this investigational therapy is a patented, first-in-class candidate targeting the myelin sheath, representing a next-step evaluation in patients with multiple sclerosis.

What unmet medical need in multiple sclerosis is Quantum BioPharma targeting with Lucid-MS?

Lucid-MS targets the large unmet need of stopping MS progression rather than only slowing it. According to Quantum BioPharma, more than 2.9 million people worldwide live with MS, and current approved therapies do not stop the disease completely.

Why is Quantum BioPharma's Lucid-MS approach to MS treatment considered different?

Lucid-MS focuses on directly targeting the myelin sheath that MS destroys, a distinct strategy versus many existing therapies. According to Quantum BioPharma, this represents a fundamentally different myelin-focused drug-discovery approach in multiple sclerosis treatment development.